Physician profile
Robert Hardi
NPI 1285693440
$5,197.98
in general payments reported to CMS, 2019-2025
19 companies · $37.74 in 2025
The $37.74 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,843 · 2020: $16.22 · 2022: $13.43 · 2023: $121 · 2024: $167 · 2025: $37.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,765.98 | 2019 | |
| Janssen Biotech, INC. | $48.63 | 2024-2025 | Stelara, Tremfya |
| Shield Therapeutics INC | $47.65 | 2024 | |
| Celgene Corporation | $41.29 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $37.05 | 2023-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.58 | 2019-2023 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $32.06 | 2024-2025 | Givlaari |
| Astrazeneca Pharmaceuticals Lp | $31.42 | 2019-2024 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $21.17 | 2019 | |
| Genzyme Corporation | $21.02 | 2024 | |
| Phathom Pharmaceuticals, INC. | $19.78 | 2024 | Voquezna |
| Amarin Pharma, INC. | $19.48 | 2023 | |
| Novo Nordisk INC | $19.13 | 2023 | Wegovy, Saxenda |
| Abbvie INC. | $16.22 | 2020 | |
| Boston Scientific Corporation | $15.98 | 2023 | Wavewriter Alpha Prime 16 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.70 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.